Radiofrequency Ablation for Papillary Thyroid Microcarcinoma
Official title: RFA Treatment for Papillary Thyroid Microcarcinoma Cohort
Run by Columbia University · NCT05189821 · Data updated 2026-11-12
This study tests if a less invasive treatment called Radiofrequency Ablation can safely help people with small thyroid cancers who can’t or don’t want to have surgery.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 50 (estimated) |
| Sponsor | Columbia University Academic / other |
| Locations | 1 site (New York, New York) |
| Status | Recruiting |
| Started | November 1, 2021 |
| Main results expected | November 2027 |
| Study ends | November 2028 |
| Registry record updated | May 29, 2026 |
| Trial ID | NCT05189821 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are adults aged 18 and older with biopsy-proven papillary thyroid microcarcinoma measuring 1.5 cm or larger who either refuse surgery or are not good surgical candidates.
✕Probably not a fit
Patients with cardiac arrhythmias or those who are pregnant will not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study evaluates the efficacy and safety of Radiofrequency Ablation (RFA) as a treatment for Papillary Thyroid Microcarcinoma (PTMC) in patients who have opted for this procedure based on their physician's recommendation. The study aims to collect data on patients who are either unwilling to undergo surgery or are not suitable surgical candidates. By focusing on less invasive treatment options, the study addresses the growing need for alternative approaches to managing indolent thyroid cancers. Participants will provide access to their medical data to assess the outcomes of RFA.
Why it matters
Potential benefit: If successful, this approach could provide a less invasive treatment option for patients with low-risk thyroid cancer, reducing the need for surgery and its associated complications.
How similar studies have gone: Other studies have shown promising results with similar less invasive approaches for treating thyroid cancers, indicating potential for success in this study.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Adult patients (\>/= 18 years) * Biopsy proven papillary thyroid microcarcinoma (\>/= 1.5cm in greatest diameter, PTMC) * Either refuse surgery or are not good surgical candidates Exclusion Criteria: * Cardiac arrhythmia * Pregnancy
Where it's running
-
Columbia University
New York, New York, United States Recruiting
Study contacts
- Principal investigator: Jennifer H Kuo, MD MS — Columbia University
- Study coordinator: Jennifer H Kuo, MD MS
- Email: jhk2029@cumc.columbia.edu
- Phone: 212-305-6969
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Microwave ablation for papillary thyroid microcarcinoma monitored with contrast-enhanced ultrasound and genetic testing
This project will try microwave ablation guided by contrast-enhanced ultrasound and an 88-gene panel in adults with low-risk papillary thyroid microcarcinoma to see if it controls the tumor while preserving thyroid function.
-
Minimally invasive treatments for thyroid cancer
This study is testing whether less invasive treatments for small thyroid cancers can safely replace surgery and improve patients' quality of life.
-
Monitoring small thyroid cancers without immediate surgery
This study tests whether watching small thyroid cancers closely instead of doing surgery right away is a safe option for patients and looks at how this choice affects their quality of life and anxiety.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.